Literature DB >> 3522438

New monoclonal antibodies specific for human sarcomas.

O Bruland, O Fodstad, S Funderud, A Pihl.   

Abstract

Monoclonal antibodies (MAbs) against sarcoma-associated cell membrane antigens were prepared by immunizing BALB/c mice with tumor cells from a human osteosarcoma, TPX, grown as a xenograft in athymic BALB/c nude mice. Spleen cells from immunized mice were hybridized with X-63 Ag. 8.653 mouse myeloma cells which yielded 260 growing hybridomas. Seven of these produced antibodies that bound to TPX cells and to cells from another osteosarcoma, but not to autologous skin fibroblasts. MAbs from 2 (TP-1 and TP-3) of these 7 clones did not cross-react with non-sarcomatous tumor cells or peripheral blood lymphocytes. Immunohistochemical studies on frozen tissue sections showed that the TP-1 (IgG-2a) and TP-3 (IgG-2b) antibodies had characteristic and identical specificity profiles. Binding of TP-1 (TP-3) was demonstrated to 15/15 (15/15) osteosarcomas, 3/3 (2/2) synovial sarcomas, 7/9 (6/8) malignant fibrous histiocytomas, 2/2 (1/1) malignant hemangiopericytomas, 1/2 (1/2) chondrosarcomas and 3/6 (1/3) unclassified sarcomas. The antibodies did not bind to any of 16 sarcomas belonging to other histological subtypes, including liposarcomas and leio- and rhabdomyosarcomas. Moreover, they failed to bind to sections of 66 different non-sarcomatous malignancies, or to any of a range of normal adult and fetal tissues, although some weak staining of proximal kidney tubules was seen. The restricted specificity of these antibodies to some major subtypes of human sarcomas makes them promising tools for identification and subclassification of sarcomas.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3522438     DOI: 10.1002/ijc.2910380106

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Immunohistochemical, quantitative immunoelectron microscopic, and DNA cytofluorometric characterization of chemically induced rat malignant fibrous histiocytoma.

Authors:  T Tsuchiya; K Takahashi; M Takeya; Y Hosokawa; T Hattori; K Takagi
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

2.  Immunocytochemical identification of osteogenic bone tumors by osteonectin antibodies.

Authors:  G Jundt; A Schulz; K H Berghäuser; L W Fisher; P Gehron-Robey; J D Termine
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

3.  Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.

Authors:  R H Larsen; O S Bruland
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

4.  Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.

Authors:  R H Larsen; O S Bruland; P Hoff; J Alstad; E K Rofstad
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

5.  Radioimmunotargeting of human tumour cells in immunocompetent animals.

Authors:  J G Fjeld; O S Bruland; H B Benestad; L Schjerven; T Stigbrand; K Nustad
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

Review 6.  Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives.

Authors:  Daniele Mercatelli; Massimo Bortolotti; Alberto Bazzocchi; Andrea Bolognesi; Letizia Polito
Journal:  Biomedicines       Date:  2018-02-10

7.  Selective localisation of two radiolabelled anti-sarcoma monoclonal antibodies in human osteosarcoma xenografts.

Authors:  O Bruland; O Fodstad; A Skretting; A Pihl
Journal:  Br J Cancer       Date:  1987-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.